Harry Scheinin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2955715/publications.pdf

Version: 2024-02-01

		186209	1	161767	
55	3,685	28		54	
papers	citations	h-index		g-index	
EO	EO	EO		2020	
58	58	58		3839	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	CITATIONS
1	Time domain, geometrical and frequency domain analysis of cardiac vagal outflow: effects of various respiratory patterns. Clinical Physiology, 2001, 21, 365-376.	0.7	425
2	Effects of Sevoflurane, Propofol, and Adjunct Nitrous Oxide on Regional Cerebral Blood Flow, Oxygen Consumption, and Blood Volume in Humans. Anesthesiology, 2003, 99, 603-613.	1.3	342
3	Effects of Surgical Levels of Propofol and Sevoflurane Anesthesia on Cerebral Blood Flow in Healthy Subjects Studied with Positron Emission Tomography. Anesthesiology, 2002, 96, 1358-1370.	1.3	254
4	Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. British Journal of Clinical Pharmacology, 2003, 56, 691-693.	1.1	223
5	Returning from Oblivion: Imaging the Neural Core of Consciousness. Journal of Neuroscience, 2012, 32, 4935-4943.	1.7	212
6	Effects of dexmedetomidine, a selective $\hat{l}\pm 2$ -adrenoceptor agonist, on hemodynamic control mechanisms. Clinical Pharmacology and Therapeutics, 1989, 46, 33-42.	2.3	203
7	Effects of Subanesthetic Doses of Ketamine on Regional Cerebral Blood Flow, Oxygen Consumption, and Blood Volume in Humans. Anesthesiology, 2003, 99, 614-623.	1.3	199
8	SÂ-Ketamine Anesthesia Increases Cerebral Blood Flow in Excess of the Metabolic Needs in Humans. Anesthesiology, 2005, 103, 258-268.	1.3	143
9	Reversal of the Sedative and Sympatholytic Effects of Dexmedetomidine with a Specific $\hat{l}\pm 2$ -Adrenoceptor Antagonist Atipamezole. Anesthesiology, 1998, 89, 574-584	1.3	128
10	Epileptiform Discharges during 2 MAC Sevoflurane Anesthesia in Two Healthy VolunteersÂ. Anesthesiology, 1999, 91, 1952-1952.	1.3	126
11	Effects of Subanesthetic Ketamine on Regional Cerebral Glucose Metabolism in Humans. Anesthesiology, 2004, 100, 1065-1071.	1.3	115
12	Intramuscular Dexmedetomidine as Premedication for General Anesthesia. Anesthesiology, 1993, 78, 1065-1075.	1.3	107
13	Effect of Inhaled Xenon on Cerebral White Matter Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest. JAMA - Journal of the American Medical Association, 2016, 315, 1120.	3.8	97
14	The Role of Heart Rate Variability in Risk Stratification for Adverse Postoperative Cardiac Events. Anesthesia and Analgesia, 2007, 105, 1548-1560.	1.1	79
15	Cardiovascular and parasympathetic effects of dexmedetomidine in healthy subjects. Canadian Journal of Physiology and Pharmacology, 2004, 82, 359-362.	0.7	67
16	Measurement of central Âμ-opioid receptor binding in vivo with PET and [11C]carfentanil: a test–retest study in healthy subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 275-286.	3.3	67
17	Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clinical Pharmacology and Therapeutics, 1992, 52, 537-546.	2.3	64
18	Interindividual variability and lateralization of \hat{l} 4-opioid receptors in the human brain. NeuroImage, 2020, 217, 116922.	2.1	60

#	Article	IF	Citations
19	Effects of Xenon Anesthesia on Cerebral Blood Flow in Humans. Anesthesiology, 2007, 106, 1128-1133.	1.3	57
20	Consciousness lost and found: Subjective experiences in an unresponsive state. Brain and Cognition, 2011, 77, 327-334.	0.8	47
21	Differentiating Drug-related and State-related Effects of Dexmedetomidine and Propofol on the Electroencephalogram. Anesthesiology, 2018, 129, 22-36.	1.3	45
22	Sevoflurane and Propofol Increase 11C-Flumazenil Binding to Gamma-Aminobutyric AcidA Receptors in Humans. Anesthesia and Analgesia, 2004, 99, 1420-1426.	1.1	41
23	The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. Psychopharmacology, 2001, 154, 343-349.	1.5	40
24	Spectral Analysis of Heart Rate Variability as a Quantitative Measure of Parasympatholytic Effect-Integrated Pharmacokinetics and Pharmacodynamics of Three Anticholinergic Drugs. Therapeutic Drug Monitoring, 1999, 21, 141-151.	1.0	37
25	Intravenous Ethanol Increases Dopamine Release in the Ventral Striatum in Humans: PET Study Using Bolus-Plus-Infusion Administration of [11C]raclopride. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 424-431.	2.4	36
26	Xenon Does Not Affect \hat{I}^3 -Aminobutyric Acid Type A Receptor Binding in Humans. Anesthesia and Analgesia, 2008, 106, 129-134.	1.1	33
27	Directional Connectivity between Frontal and Posterior Brain Regions Is Altered with Increasing Concentrations of Propofol. PLoS ONE, 2014, 9, e113616.	1.1	31
28	Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest. Journal of the American College of Cardiology, 2017, 70, 2652-2660.	1.2	30
29	Foundations of Human Consciousness: Imaging the Twilight Zone. Journal of Neuroscience, 2021, 41, 1769-1778.	1.7	30
30	Analysis of rapid heart rate variability in the assessment of anticholinergic drug effects in humans. European Journal of Clinical Pharmacology, 2005, 61, 559-565.	0.8	29
31	Subanesthetic Ketamine Does Not Affect 11C-Flumazenil Binding in Humans. Anesthesia and Analgesia, 2005, 101, 722-725.	1.1	26
32	The Effects of Xenon Anesthesia on the Relationship Between Cerebral Glucose Metabolism and Blood Flow in Healthy Subjects: A Positron Emission Tomography Study. Anesthesia and Analgesia, 2009, 108, 593-600.	1.1	26
33	CYP2D6 polymorphism is not crucial for the disposition of selegiline*. Clinical Pharmacology and Therapeutics, 1998, 64, 402-411.	2.3	23
34	Enhanced Noradrenergic Neuronal Activity Increases Homovanillic Acid Levels in Cerebrospinal Fluid. Journal of Neurochemistry, 1986, 47, 665-667.	2.1	23
35	Hormonal effects of MPVâ€2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study. British Journal of Clinical Pharmacology, 1998, 45, 141-146.	1.1	21
36	Biological Day-to-Day Variation and Reference Change Limits of Serum Cortisol and Aldosterone in Healthy Young Men on Unrestricted Diets. Clinical Chemistry, 1999, 45, 1097-1099.	1.5	18

#	Article	IF	Citations
37	Alpha band frontal connectivity is a state-specific electroencephalographic correlate of unresponsiveness during exposure to dexmedetomidine and propofol. British Journal of Anaesthesia, 2020, 125, 518-528.	1.5	17
38	Sleep apnoea is associated with major cardiac events in peripheral arterial disease. European Respiratory Journal, 2014, 43, 1652-1660.	3.1	14
39	Validation of <scp>[¹¹C]ORMâ€13070</scp> as a <scp>PET</scp> tracer for alpha _{2c} â€adrenoceptors in the human brain. Synapse, 2015, 69, 172-181.	0.6	14
40	Single-subject analysis of N400 event-related potential component with five different methods. International Journal of Psychophysiology, 2019, 144, 14-24.	0.5	14
41	Seasonal Variation in the Brain \hat{l} ¹ /4-Opioid Receptor Availability. Journal of Neuroscience, 2021, 41, 1265-1273.	1.7	14
42	The influence of drug input rate on the development of tolerance to frusemide. British Journal of Clinical Pharmacology, 1998, 46, 479-487.	1.1	13
43	Alterations in heart rate variability in patients with peripheral arterial disease requiring surgical revascularization have limited association with postoperative major adverse cardiovascular and cerebrovascular events. PLoS ONE, 2018, 13, e0203519.	1.1	13
44	Sensitivity of [11C]ORM-13070 to increased extracellular noradrenaline in the CNS – a PET study in human subjects. Psychopharmacology, 2015, 232, 4169-4178.	1,5	12
45	Detecting a dexmedetomidine-evoked reduction of noradrenaline release in the human brain with the alpha2C-adrenoceptor PET ligand [11C]ORM-13070. Synapse, 2016, 70, 57-65.	0.6	10
46	The influence of dexmedetomidine and propofol on circulating cytokine levels in healthy subjects. BMC Anesthesiology, 2019, 19, 222.	0.7	10
47	Pharmacokinetic–pharmacodynamic model for the anticholinergic effect of glycopyrrolate. European Journal of Clinical Pharmacology, 2001, 57, 153-158.	0.8	9
48	Buccal delivery of an $\hat{1}\pm 2$ -adrenergic receptor antagonist, atipamezole, in humans*. Clinical Pharmacology and Therapeutics, 1995, 58, 506-511.	2.3	7
49	Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. British Journal of Clinical Pharmacology, 2001, 52, 702-704.	1.1	6
50	Harnessing anesthesia and brain imaging for the study of human consciousness. Current Pharmaceutical Design, 2014, 20, 4211-24.	0.9	6
51	Using Positron Emission Tomography in Revealing the Mystery of General Anesthesia: Study Design Challenges and Opportunities. Methods in Enzymology, 2018, 603, 279-303.	0.4	5
52	Nocturnal body movements and hypoxemia in middle-aged females after lower abdominal surgery under general anesthesia: a study with the static-charge-sensitive bed (SCSB). Journal of Clinical Monitoring and Computing, 1998, 14, 239-244.	0.7	4
53	Effect of Inhaled Xenon on Cardiac Function in Comatose Survivors of Out-of-Hospital Cardiac Arrestâ€"A Substudy of the Xenon in Combination With Hypothermia After Cardiac Arrest Trial. , 2021, 3, e0502.		4
54	Monoamine Metabolite Levels in Rat CSF: Kinetic Studies. Basic and Clinical Pharmacology and Toxicology, 1987, 61, 167-171.	0.0	2

#	Article	lF	CITATIONS
55	On no man's land: Subjective experiences during unresponsive and responsive sedative states induced by four different anesthetic agents. Consciousness and Cognition, 2021, 96, 103239.	0.8	2